Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function.

BACKGROUND Men with chronic lung disease (CLD) are at risk for osteoporosis, but the relative contributions of their chronic pulmonary disease, glucocorticoid therapy, and other factors toward loss of bone has not been established. Understanding the relative importance of these factors would assist in selecting patients for bone densitometry screening and in policy decisions regarding Medicare reimbursement. OBJECTIVE To identify patients with CLD who are most likely to benefit from bone densitometry screening based on clinical and biochemical measures. DESIGN Cross-sectional medical survey. PATIENTS Patients with CLD who were treated with either oral, inhaled, or no glucocorticoid therapy. A control group without lung disease was recruited from the same clinic population. MEASUREMENTS Dual-energy X-ray absorptiometry was obtained for each group, and the association between bone mass and clinical variables, glucocorticoid use, gonadal hormones, and biochemical markers of bone metabolism was determined. RESULTS Osteoporosis (a T score < -2.5 at the hip or spine) was five times as likely in patients with CLD as in control subjects. Although the prevalence of osteoporosis was higher (ninefold) after chronic glucocorticoid therapy, patients with CLD who had never been treated with glucocorticoids had a substantial (fourfold) risk of osteoporosis. Chronic inhaled glucocorticoid therapy offered no protection from bone loss compared to treatment with oral glucocorticoids. Of the clinical and biochemical measures that were obtained, bone mass was weakly correlated with body mass index (BMI), serum estradiol-17beta, and N-telopeptide, but not with testosterone, alkaline phosphatase, bone-specific alkaline phosphatase, or osteocalcin. CONCLUSION Patients with CLD should be considered for bone densitometry screening regardless of glucocorticoid use. Those patients with a low BMI and/or decreased serum estradiol-17beta comprise a subgroup with increased risk for osteoporosis.

[1]  I. Reid Glucocorticoid-induced osteoporosis. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[2]  E. Seeman Osteoporosis in men , 1997, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[3]  E. Seeman,et al.  Osteoporosis in Men , 1999, Osteoporosis International.

[4]  W. O'Fallon,et al.  Bone Density and Fracture Risk in Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  E. Orwoll,et al.  Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. , 1998, The Journal of clinical endocrinology and metabolism.

[6]  J. Bilezikian,et al.  Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. , 1998, The New England journal of medicine.

[7]  M. Mussolino,et al.  Risk Factors for Hip Fracture in White Men: The NHANES I Epidemiologic Follow‐up Study , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Anderson Fh Osteoporosis in men. , 1998 .

[10]  C. Mcevoy,et al.  Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[11]  H. Magnussen,et al.  Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. , 1998, The European respiratory journal.

[12]  L. J. rd Epidemiology of spinal osteoporosis. , 1997 .

[13]  I. Reid Glucocorticoid osteoporosis--mechanisms and management. , 1997, European journal of endocrinology.

[14]  T. Link,et al.  Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.

[15]  K. Korach,et al.  Effect of testosterone and estradiol in a man with aromatase deficiency. , 1997, The New England journal of medicine.

[16]  E. Heikkinen,et al.  Calcaneal Bone Mineral Density Predicts Fracture Occurrence: A Five‐Year Follow‐up Study in Elderly People , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  H. Mulder,et al.  The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. , 1997, The Netherlands journal of medicine.

[18]  R. Francis,et al.  Androgen Supplementation in Eugonadal Men with Osteoporosis: Effects of Six Months' Treatment on Markers of Bone Formation and Resorption , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  P. Miller,et al.  Prediction of fracture risk. I: Bone density. , 1996, The American journal of the medical sciences.

[20]  A. Iranmanesh,et al.  Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[21]  P. Ross Osteoporosis. Frequency, consequences, and risk factors. , 1996, Archives of internal medicine.

[22]  H K Genant,et al.  Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. , 1996, Seminars in arthritis and rheumatism.

[23]  J. Adachi Corticosteroid-induced osteoporosis. , 1996, Drug and therapeutics bulletin.

[24]  E. Barrett-Connor,et al.  Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. , 1995, American journal of public health.

[25]  E. Simpson,et al.  Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. , 1995, The Journal of clinical endocrinology and metabolism.

[26]  J. Baskerville,et al.  Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. , 1995, The Journal of allergy and clinical immunology.

[27]  Harry K. Genant,et al.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. , 1993, The American journal of medicine.

[28]  B. Lukert,et al.  Glucocorticoid-induced osteoporosis , 2004 .

[29]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[30]  C. Slemenda,et al.  Long-Term Bone Loss in Men: Effects of Genetic and Environmental Factors , 1992, Annals of Internal Medicine.

[31]  M. V. Van Natta,et al.  Hip fractures among the elderly: factors associated with in-hospital mortality. , 1991, American journal of epidemiology.

[32]  P. Rüegsegger,et al.  Does alternate‐day cloprednol therapy prevent bone loss? A longitudinal double‐blind, controlled clinical study , 1990, Clinical pharmacology and therapeutics.

[33]  C. Dulberg,et al.  Relationship of lung function to severity of osteoporosis in women. , 1990, The American review of respiratory disease.

[34]  E. Bonucci,et al.  Bone loss in response to long-term glucocorticoid therapy. , 1990, Bone and mineral.

[35]  T. Suda,et al.  Studies on pituitary-gonadal function in patients with Cushing's syndrome. , 1988, Endocrinologia japonica.

[36]  J. Luton,et al.  Reversible gonadotropin deficiency in male Cushing's disease. , 1977, The Journal of clinical endocrinology and metabolism.